Synapse - Works

Results (2146)

Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial

Meeting Abstract

Konstantinopoulos, P.; Kim, J. W.; Freyer, G.; Lee, J. Y.; Gaba, L.; Grisham, R.; Colombo, N.; Wu, X.; Sehouli, J.; Cruz, F.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Efficacy and safety of trastuzumab deruxtecan among patients with HER2-expressing solid tumors: Biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study

Meeting Abstract

Makker, V.; Oaknin, A.; Manso, L.; González-Martín, A.; Lugowska, I.; Meric-Bernstam, F.; Lorusso, D.; Banerjee, S.; Liao, J.; Siena, S.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)

Meeting Abstract

Højgaard, M.; Yap, T. A.; Lee, E. K.; Weiss, M. C.; Lheureux, S.; Simpkins, F.; LoRusso, P.; Carneiro, B. A.; Moy, R. H.; Aguado-Fraile, E.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): The ReFocus study

Meeting Abstract

Hollebecque, A.; Dotan, E.; Liao, C. Y. A.; Roda, D.; Fontana, E.; Babiker, H.; Kim, R. D.; Oh, D. Y.; Ghiringhelli, F.; Moreno, I.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

First clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4

Meeting Abstract

Yap, T. A.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Moreno Garcia, V.; Punekar, S. R.; Calvo, E.; Sonpavde, G. P.; Awad, M.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, randomized, placebo-controlled, double-blind, multicenter trial of Selinexor in maintenance therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma

Meeting Abstract

Webber, K.; Vergote, I.; Mirza, M. R.; Coleman, R.; Fidalgo, J. A. P.; Monk, B. J.; Valabrega, G.; Slomovitz, B.; Van Gorp, T.; Moore, K.; more...
Asia-Pacific Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Longer-term safety and efficacy of selinexor maintenance therapy for patients with TP53wt advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

Meeting Abstract

Haluska, P.; Pérez-Fidalgo, J. A.; Vergote, I.; Hamilton, E.; de Giorgi, U.; Van Gorp, T.; Lübbe, K.; Zikan, M.; Helpman, L.; Miller, D. S.; more...
Asia-Pacific Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors

Meeting Abstract

Doi, T.; Patel, M. R.; Koyama, T.; Falchook, G. S.; Friedman, C.; Piha-Paul, S. A.; Gutierrez, M.; Awad, M.; Mattour, A.; Satoh, T.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Optimizing mainstreaming of genetic testing in parallel with ovarian and endometrial cancer tumor testing: How do we maximize our impact?

Journal Article

Liu, Y. L.; Sia, T. Y.; Varice, N.; Wu, M.; Byrne, M.; Khurram, A.; Kemel, Y.; Sheehan, M.; Galle, J.; Sabbatini, P.; more...
JCO Precision Oncology (2024)

Fulltext@MSK | Save

Advancing global health equity in oncology clinical trial access

Editorial

Bloomberg New Economy International Cancer Coalition; McKinsey Cancer Center; Cure4Cancer
Cancer Discovery (2024)

Fulltext@MSK | Save